Members

The Lupus ABC convenes regulators, drug developers, academics, patient-focused non-profits, professional societies, and government representatives in a pre-competitive setting to collaboratively develop and implement a community-wide action plan that addresses the most pressing drug development issues in Systemic Lupus Erythematosus (SLE), Lupus Nephritis, and Primary Cutaneous Lupus.

The power of the collective community input, including the regulatory and patient perspectives within the Lupus ABC, has the potential to make a significant and immediate impact on accelerating the approvals of therapies for lupus.

Membership is open to patient organizations, academic institutions, companies, federal agencies, and other entities committed to active and consistent participation in the PPP’s work to advance the development of new treatments and cures for lupus. For further information on Lupus ABC and membership, please sign up or contact Nicole Cooper at ncooper@lupusresearch.org.

  • AbbVie**
  • Adicet Bio**
  • Alumis, Inc.**
  • American College of Rheumatology (ACR)
  • Amgen**
  • AstraZeneca*
  • Biogen*
  • Bristol Myers Squibb*
  • Cabaletta Bio**
  • Caribou Bio**
  • Center for Biologics Evaluation and Research (CBER), U.S. Food & Drug Administration (FDA)
  • Center for Drug Evaluation and Research (CDER), U.S. Food & Drug Administration (FDA)
  • Childhood Arthritis and Rheumatology Research Alliance (CARRA)
  • Eli Lilly and Company*
  • EMD Serono*
  • Fate Therapeutics**
  • Genentech*
  • Gilead Sciences, Inc.*
  • GSK*
  • iCell Gene Therapeutics**
  • Janssen**
  • Kaleidoscope Fighting Lupus
  • Kyverna Therapeutics**
  • Louisiana Lupus Foundation, Inc.
  • Lupus Foundation of America
  • Lupus Foundation of Colorado
  • Lupus Foundation of New England
  • Lupus Foundation of Southern California
  • Lupus Research Alliance
  • Lupus Society of Illinois
  • Lupus Therapeutics / Lupus Clinical Investigators Network
  • Merck**
  • Michigan Lupus Foundation
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
  • National Institute for Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
  • Nkarta**
  • Novartis**
  • PPD**
  • Rome Therapeutics**
  • Sana**
  • Sanofi**
  • Synthekine**
  • Takeda**
Visionary Sponsor* | Innovator Sponsor**

As of March 27, 2024